Dr. Kari Ring and Dr. Susan Modesitt are Co-Directors of UVA’s High Risk Breast and Ovarian Cancer clinic that was established in 2007 to provide individualized genetic risk assessment, customized cancer screening and cancer risk reducing medications or surgeries to women at high risk to develop cancer. Women with BRCA1 mutations have an extremely high risk of developing ovarian cancer but it is thought that the majority of ovarian cancers may start in the fallopian tubes. Trials are needed to determine if it is safe to remove the fallopian tubes only and delay or omit removing the ovaries (and allowing women to keep their hormones) until women go through menopause.
Dr. Ring is the Principal Investigator of a new Clinical Trial opportunity at UVA that is also being run nationwide called “A NON-RANDOMIZED PROSPECTIVE CLINICAL TRIAL COMPARING THE NON-INFERIORITY OF SALPINGECTOMY TO SALPINGO-OOPHORECTOMY TO REDUCE THE RISK OF OVARIAN CANCER AMONG BRCA1 CARRIERS [SOROCk]”. Of note, UVA enrolled the first patient in the country on this important clinical trial.
Women who enroll in this study will have the choice between 1) having only their fallopian tubes removed or 2) having both the fallopian tubes and the ovaries removed. Both groups will be followed closely to ensure safety and to see how women’s quality of life is impacted by surgery.
For more information on this trial, please refer to: NCT04251052